Expérimentation préclinique et recherche clinique
FDG-PET/CT in Lymphoma: Where Do We Go Now?, Al Tabaa, Y ; Bailly, C ; Kanoun, S, Cancers (Basel), 2021, 13
https://doi.org/10.3390/cancers13205222Promising Clinical Performance of Pretargeted Immuno-PET with Anti-CEA Bispecific Antibody and Gallium-68-Labelled IMP-288 Peptide for Imaging Colorectal Cancer Metastases: A Pilot Study, Touchefeu, Y.; Bailly, C.; Frampas, E.; Eugène, T.; Rousseau, C.; Bourgeois, M.; Bossard, C.; Faivre-Chauvet, A.; Rauscher, A.; Masson, D.; David, A.; Cerato, E.; Carlier, T.; Sharkey, R. M.; Goldenberg, D. M.; Barbet, J.; Kraeber-Bodere, F.; Bodet-Milin, C., Eur J Nucl Med Mol Imaging 2021, 48 (3), 874–882. doi:10.1007/s00259-020-04989-3
Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the IPET-MTC Study, Bodet-Milin, C.; Faivre-Chauvet, A.; Carlier, T.; Ansquer, C.; Rauscher, A.; Frampas, E.; Toulgoat, F.; Masson, D.; Bourgeois, M.; Cerato, E.; Rohmer, V.; Couturier, O.; Drui, D.; Goldenberg, D. M.; Sharkey, R. M.; Barbet, J.; Kraeber-Bodere, F., J Nucl Med 2021, 62 (9), 1221–1227. doi:10.2967/jnumed.120.252791
Copper-64-Labeled 1C1m-Fc, a New Tool for TEM-1 PET Imaging and Prediction of Lutetium-177-Labeled 1C1m-Fc Therapy Efficacy and Safety, Delage JA, Gnesin S, Prior JO, Barbet J, Le Saëc P, Marionneau-Lambot S, Gouard S, Chérel M, Bourgeois M, Schaefer N, Viertl D, Fierle JK, Dunn SM, Faivre-Chauvet A. Cancers (Basel). 2021 Nov 25;13(23):5936.
doi:10.3390/cancers13235936Impact of DOTA Conjugation on Pharmacokinetics and Immunoreactivity of [177Lu]Lu-1C1m-Fc, an Anti TEM-1 Fusion Protein Antibody in a TEM-1 Positive Tumor Mouse Mode, Delage JA, Faivre-Chauvet A, Barbet J, Fierle JK, Schaefer N, Coukos G, Viertl D, Dunn SM, Gnesin S, Prior JO, Pharmaceutics. 2021 Jan 13;13(1):96. doi: 10.3390/pharmaceutics13010096